Dan Roden

The Precision Medicine Initiative is a national effort announced by President Obama during his State of the Union address to provide more effective treatment and prevention strategies for individuals by taking into account their unique genetic, environmental and lifestyle factors. Read More

Dan Roden, M.D., assistant vice chancellor for Personalized Medicine, has been appointed to the National Advisory Council for Human Genome Research of the National Institutes of Health (NIH). Read More

Tacrolimus is essential for patients receiving new hearts, kidneys and other organ transplants. The drug suppresses the body’s immune system, helping to prevent rejection. Read More

Since it was founded in 1963, the Vanderbilt Division of Clinical Pharmacology has pioneered “translational science” and continues to transform medical practice worldwide, speakers at the division’s 50th anniversary scientific symposium said last week. Read More

Dan Roden, M.D., assistant vice chancellor for Personalized Medicine and William Stokes Professor of Experimental Therapeutics, received a 2012 Distinguished Scientist Award at the annual Scientific Sessions of the American Heart Association (AHA) last week in Los Angeles. Read More

During a meeting in Nashville last week, the director of the National Institutes of Health (NIH) called on academic medical centers to make the case for continued, strong federal investment in biomedical research. Read More

Watch video of the Chancellor’s Lecture Series, featuring a talk by Dr. Dan Roden: “Genomes, Hype, and a Realistic Pathway to Personalized Medicine” Roden is widely-recognized for his expertise in clinical, genetic, cellular, and molecular basis of arrhythmia susceptibility and variability responses to arrhythmia therapies. Over the past decade, he… Read More

The first Chancellor’s Lecture of the academic year, entitled “Genomes, Hype and a Realistic Pathway to Personalized Medicine,” will be given Wednesday, Sept. 12, by Dan Roden, M.D., assistant vice chancellor for Personalized Medicine at Vanderbilt University. Read More

This month BioVU logged in its 150,000th unique genetic sample. It is now the world’s largest collection of human DNA linked to searchable, electronic health information. Read More

Females may be at higher risk of potentially fatal heart condition due to gender differences in a protein involved in the heart’s electrical activity. Read More

Vanderbilt researchers are seeking genetic clues to explain why risk factors for AF are more prevalent in African-Americans but their incidence of the disease is lower than European-Americans. Read More

Watch video of Dr. Dan Roden speaking about personalized medicine. Roden spoke Jan. 25 as part of the Osher Lifelong Learning class, “Medical Advances.” The course is presented by faculty of the Vanderbilt University Medical Center and focuses on what the future of medicine holds. Physicians are now able to use… Read More

Individuals with atrial fibrillation who have a particular genetic variant respond better to rate control therapy. Read More

The U.S. Centers for Disease Control and Prevention has awarded Vanderbilt researchers a two-year, $1 million grant to Vanderbilt to develop a model for applying genomic testing to drug prescribing in “real-world” settings. Read More

Vanderbilt University Medical Center doctors announced today they will begin screening patients who take commonly prescribed statin drugs for a rare genetic variation that can increase risks for side effects from these drugs such as muscle aches, kidney damage and even death. Read More

Vanderbilt University Medical Center is a laboratory for health care reform. Increasingly, Vanderbilt researchers are applying their expertise in informatics, genomics, drug discovery, basic science and clinical medicine to the solution of critical problems in patient care. Bedside checklists and electronic “dashboards” developed at Vanderbilt, for example, enable doctors and… Read More